Sanofi is ending a Phase 2 clinical trial that's testing a drug from Denali for multiple sclerosis, ending the development ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

The FDA has approved Roche’s inavolisib plus Pfizer's Ibrance and fulvestrant in a subtype of breast cancer over a month ...

Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the ...

Heart-breaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won ...

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

Suki, a startup that provides AI tools to help healthcare providers with documentation, billing and other administrative work ...

Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup ...

CDMOs are increasingly fielding inquiries from biopharma clients on how reliant they are on China for their raw materials, ...

Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an ...

When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in ...